HemostOD is assembling a novel, cell-based production platform based on natural human biology that makes blood platelets for transfusion in hours, not the days taken by its competitors. In pre-clinical development, the technology manufactures blood platelets outside the body from genetically modified CD34+ adult stem cells, rapidly and scalably, as a substitute to platelets from blood donors, which are in perennial short supply.
News
